Search | Clinical Trials Finder

Conditions: Head and Neck Cancer, Mucositis Oral, Radiation Toxicity, Tongue Cancer
Interventions: sargramostim, oral salt and soda mouthwash; Biological · Other
Lead sponsor: Marilyn Dodd; Other
Eligibility: 18 Years and older
Enrollment: 91 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Leukemia
Interventions: filgrastim, recombinant interferon alfa, sargramostim, therapeutic autologous lymphocytes, carmustine, cyclophosphamide, etoposide, gemcitabine hydrochloride, melphalan, bone marrow ablation with stem cell support, in vitro-treated peripheral blood stem cell transplantation; Biological · Drug · Procedure
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: Up to 120 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2008
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Ganglioneuroblastoma, High Risk Neuroblastoma
Interventions: Autologous Hematopoietic Stem Cell Transplantation, Carboplatin, Cisplatin, Cyclophosphamide, Dexrazoxane, Dinutuximab, Doxorubicin, Etoposide, External Beam Radiation Therapy, Isotretinoin, Melphalan, Sargramostim, Thiotepa, Topotecan, Vincristine; Procedure · Drug · Biological + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Up to 30 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 7
States / cities: Los Angeles, California • Washington D.C., District of Columbia • Boston, Massachusetts + 4 more

Conditions: Sarcoma
Interventions: NY-ESO-1 peptide vaccine, sargramostim; Biological
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2005
U.S. locations: 1
States / cities: New York, New York

Conditions: Colorectal Cancer
Interventions: edrecolomab, sargramostim; Biological
Lead sponsor: James Ahlgren; Other
Eligibility: 18 Years to 120 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1995 – 2017
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Metastatic Melanoma
Interventions: AV-MEL-1; Drug
Lead sponsor: Aivita Biomedical, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 2
States / cities: Irvine, California • Newport Beach, California

Conditions: Leukemia, Myelodysplastic Syndromes
Interventions: filgrastim, sargramostim, cytarabine, daunorubicin hydrochloride, zosuquidar trihydrochloride, Placebo; Biological · Drug
Lead sponsor: Eastern Cooperative Oncology Group; Network
Eligibility: 60 Years and older
Enrollment: 449 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2002
U.S. locations: 91
States / cities: Scottsdale, Arizona • Aurora, Colorado • Boulder, Colorado + 67 more

Conditions: Stage III Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7
Interventions: Biospecimen Collection, Computed Tomography, Echocardiography Test, Ipilimumab, Magnetic Resonance Elastography, Multigated Acquisition Scan, Nivolumab, Sargramostim; Procedure · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2033
U.S. locations: 763
States / cities: Birmingham, Alabama • Kingman, Arizona • Little Rock, Arkansas + 494 more

Conditions: Bilateral Breast Carcinoma, Breast Inflammatory Carcinoma, Stage IB Breast Cancer AJCC v7, Stage II Breast Cancer AJCC v6 and v7, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7, Stage III Breast Cancer AJCC v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7, Triple-Negative Breast Carcinoma, Unilateral Breast Carcinoma
Interventions: Cyclophosphamide, Laboratory Biomarker Analysis, Multi-epitope Folate Receptor Alpha Peptide Vaccine, Placebo Administration, Sargramostim; Drug · Other · Biological
Lead sponsor: Academic and Community Cancer Research United; Other
Eligibility: 18 Years and older · Female only
Enrollment: 280 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2026
U.S. locations: 12
States / cities: Scottsdale, Arizona • Duarte, California • Jacksonville, Florida + 8 more

Conditions: Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Triple-Negative Breast Carcinoma
Interventions: CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine, Recombinant Granulocyte-Macrophage Colony-Stimulating Factor, Biospecimen Collection; Biological · Drug · Procedure
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Colorectal Cancer, Metastatic Cancer
Interventions: falimarev, inalimarev, sargramostim, therapeutic autologous dendritic cells; Biological
Lead sponsor: Michael Morse, MD; Other
Eligibility: 18 Years and older
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2013
U.S. locations: 6
States / cities: Washington D.C., District of Columbia • Tampa, Florida • Durham, North Carolina + 3 more

Conditions: Type and Grade of Toxicities, Demographic and Background Characteristics, Advanced, Metastatic, Recurrent Adenocarcinoma and Malignant Solid Neoplasm
Interventions: LabVax 3(22)-23 and GM-CSF (adjuvant) in combination with pembrolizumab; Combination Product
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2035
U.S. locations: 4
States / cities: Long Beach, California • Sacramento, California • San Francisco, California + 1 more

Conditions: Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia
Interventions: Galinpepimut-S, GM-CSF, Montanide; Biological · Other
Lead sponsor: Sellas Life Sciences Group; Industry
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 1
States / cities: New York, New York

Conditions: Lymphoma, Myeloma, Leukemia, Myelodysplasia, Solid Tumors
Interventions: Campath Purged Non-myeloablative ASCT, Donor Apheresis; Drug · Procedure
Lead sponsor: David Rizzieri, MD; Other
Eligibility: 17 Years and older
Enrollment: 176 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2013
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Crohn Disease
Interventions: Sargramostim (Leukine); Drug
Lead sponsor: Genzyme, a Sanofi Company; Industry
Eligibility: 18 Years and older
Enrollment: 378 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2006
U.S. locations: 98
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Berkeley, California + 80 more

Conditions: HIV Infections, Cytopenias
Interventions: Zidovudine, Sargramostim; Drug
Lead sponsor: Sandoz; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: HIV Infections
Interventions: HIV CTL MEP administered with RC529-SE adjuvant, GM-CSF; Biological · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 40 Years
Enrollment: 96 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2006
U.S. locations: 7
States / cities: Birmingham, Alabama • San Francisco, California • Baltimore, Maryland + 4 more

Conditions: Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cavity Cancer
Interventions: ALVAC(2)-NY-ESO-1(M)/TRICOM vaccine, Sargramostim; Biological
Lead sponsor: Ludwig Institute for Cancer Research; Other
Eligibility: 18 Years and older · Female only
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 2
States / cities: Buffalo, New York • New York, New York

Conditions: Malignant Neoplasms of Brain
Interventions: PEP-3 vaccine, sargramostim, Temozolomide; Biological · Drug
Lead sponsor: John Sampson; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2016
U.S. locations: 2
States / cities: Durham, North Carolina • Houston, Texas

Conditions: Lymphoma
Interventions: keyhole limpet hemocyanin, sargramostim, tumor cell-based vaccine therapy; Biological
Lead sponsor: University of Nebraska; Other
Eligibility: 18 Years to 120 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2003
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: HIV Infections
Interventions: Hepatitis B virus vaccine with GM-CSF adjuvant, Hepatitis B virus vaccine; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2008
U.S. locations: 11
States / cities: Chicago, Illinois • St Louis, Missouri • New York, New York + 6 more

Conditions: Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Malignant Neoplasm in the Lung, Metastatic Melanoma, Recurrent Melanoma, Unresectable Melanoma
Interventions: Aerosol Sargramostim, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Medical Device Usage and Evaluation, Nivolumab; Biological · Procedure · Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Malignant Melanoma
Interventions: INKT, GM-CSF; Biological · Drug
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2015
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
Interventions: sargramostim, bexarotene, cytogenetic analysis, fluorescence in situ hybridization, flow cytometry, laboratory biomarker analysis, biopsy; Biological · Drug · Genetic + 2 more
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years to 120 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2016
U.S. locations: 1
States / cities: Baltimore, Maryland

Search by objective public record fields.

GM-CSF Mouthwash for Preventing and Treating Mucositis in Patients Undergoing Radiation Therapy for Head and Neck Cancer

Chemotherapy and Peripheral Stem Cell Transplantation Followed by Immunotherapy in Treating Patients With Chronic Myelogenous Leukemia

Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma

Vaccine Therapy and Sargramostim in Treating Patients With Soft Tissue Sarcoma

Monoclonal Antibody Therapy and Colony- Stimulating Factor in Treating Patients With Metastatic Colorectal Cancer

Safety of AV-MEL-1 With Anti-PD-1 Therapy in Metastatic Melanoma

Daunorubicin & Cytarabine +/- Zosuquidar inTreating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or Refractory Anemia

A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced Melanoma

Multi-epitope Folate Receptor Alpha Peptide Vaccine, GM-CSF, and Cyclophosphamide in Treating Patients With Triple Negative Breast Cancer

A Vaccine (STEMVAC) for Improving Survival in Patients With Triple-Negative Breast Cancer and Moderate or Extensive Residual Cancer Burden

Vaccine Therapy in Treating Patients With Liver or Lung Metastases From Colorectal Cancer

Labyrinthin Vaccination in Veterans With Lung Adenocarcinoma

WT1 Vaccine Treatment of Patients in Remission From Acute Myeloid Leukemia (AML) or Acute Lymphoblastic Leukemia (ALL)

Allo Non-Myeloablative SCT Utilizing Mis-Matched Family Member Stem Cells Purged Using Campath

Open-label Trial of Leukine in Active Crohn's Disease

A Pilot Trial Evaluating an Alternating Schedule of Recombinant Human GM-CSF and Azidothymidine in Patients With HIV Infection and Leukopenia

Safety of and Immune Response to a New HIV Vaccine: HIV CTL MEP

Vaccine Therapy in Stage II, III, or IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancers

Vaccine Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

Vaccine Therapy Plus Sargramostim Following Chemotherapy in Treating Stage III or Stage IV Non-Hodgkin's Lymphoma

Safety and Effectiveness of an Adjuvant in Improving Immune Response to Hepatitis B Virus Vaccine in HIV Infected Individuals

Aerosolized Sargramostim Added to Immunotherapy for the Treatment of Patients With Metastatic Melanoma to the Lung

In Vitro Expanded Autologous Invariant Natural Killer Cells in Cancer

Bexarotene and GM-CSF in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia